Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients

British Journal of Cancer

Volumn 108, Issue 5, 2013, Pages 1034-1041

  Huillard, O ^a   Mir, O ^a   Peyromaure, M ^a   Tlemsani, C ^a   Giroux, J ^a   Boudou Rouquette, P ^a   Ropert, S ^a   Delongchamps, N Barry ^a   Zerbib, M ^a   Goldwasser, F ^a  

^a University Paris Descartes ^*  (France)

Author keywords

angiogenesis inhibitors; renal cell carcinoma; sarcopenia; sunitinib; treatment outcomes; VEGF A

Indexed keywords

SUNITINIB;

ADULT; AGED; ANOREXIA; ASTHENIA; BODY COMPOSITION; BODY MASS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DOSE LIMITING TOXICITY; DRUG WITHDRAWAL; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INCIDENCE; KIDNEY CANCER; MACROPHAGE ACTIVATION SYNDROME; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE ATROPHY; NAUSEA; PARAMETERS; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PREDICTIVE VALUE; PRIORITY JOURNAL; PROCTOCOLITIS; PROTEINURIA; RASH; RETROSPECTIVE STUDY; REVIEW; STOMATITIS; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BODY MASS INDEX; CARCINOMA, RENAL CELL; FEMALE; FORECASTING; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; PYRROLES; RETROSPECTIVE STUDIES; SARCOPENIA;

EID: 84875467554     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.58     Document Type: Review

References (28)

1. Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB (2010a) Low bodymass index and sarcopenia associated with dose-limiting toxicity ofsorafenib in patients with renal cell carcinoma. Ann Oncol 21 (8) :1594-1598.
2. Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B, Baracos VE (2010b) Association of skeletal muscle wasting with treatment with sorafenibin patients with advanced renal cell carcinoma: results from aplacebo-controlled study. J Clin Oncol 28 (6) : 1054-1060.
3. Barrios CH, Hernandez-Barajas D, Brown MP, Lee SH, Fein L, Liu JH, Hariharan S, Martell BA, Yuan J, Bello A, Wang Z, Mundayat R, Rha SY (2012) Phase II trial of continuous once-daily dosing of sunitinib asfirst-line treatment in patients with metastatic renal cell carcinoma.Cancer 118 (5) : 1252-1259.
4. Chow LQ, Eckhardt SG (2007) Sunitinib: from rational design to clinicalefficacy. J Clin Oncol 25 (7) : 884-896.
5. Cosqueric G, Sebag A, Ducolombier C, Thomas C, Piette F, Weill-Engerer S (2006) Sarcopenia is predictive of nosocomial infection in care of theelderly. Br J Nutr 96 (5) : 895-901.
6. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, Martin FC, Michel JP, Rolland Y, Schneider SM, Topinkova E, Vandewoude M, Zamboni M (2010) Sarcopenia: European consensus ondefinition and diagnosis: report of the European Working Group onsarcopenia in older people. Age Ageing 39 (4) : 412-423.
7. Escudier B, Roigas J, Gillessen S, Harmenberg U, Srinivas S, Mulder SF, Fountzilas G, Peschel C, Flodgren P, Maneval EC, Chen I, Vogelzang NJ (2009) Phase II study of sunitinib administered in a continuous once-dailydosing regimen in patients with cytokine-refractory metastatic renal cellcarcinoma. J Clin Oncol 27 (25) : 4068-4075.
8. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, DeprimoS, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oralmultitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol24 (1) : 25-35.
9. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE (2011) Definition and classification of cancer cachexia: aninternational consensus. Lancet Oncol 12 (5) : 489-495.
10. Garcia-Donas J, Esteban E, Leandro-Garcia LJ, Castellano DE, del Alba AG, Climent MA, Arranz JA, Gallardo E, Puente J, Bellmunt J, Mellado B, Martinez E, Moreno F, Font A, Robledo M, Rodriguez-Antona C (2011) Single nucleotide polymorphism associations with response and toxiceffects in patients with advanced renal-cell carcinoma treated withfirst-line sunitinib: a multicentre, observational, prospective study.Lancet Oncol 12 (12) : 1143-1150.
11. Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C (2008) Epidemiologicand socioeconomic burden of metastatic renal cell carcinoma (mRCC) : aliterature review. Cancer Treat Rev 34 (3) : 193-205.
12. Heymsfield SB, Wang Z, Baumgartner RN, Ross R (1997) Human bodycomposition: advances in models and methods. Annu Rev Nutr 17: 527-558.
13. Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, Khayat D, Spano JP (2009) Management of hypertension in angiogenesis inhibitortreatedpatients. Ann Oncol 20 (5) : 807-815.
14. Mir O, Coriat R, Blanchet B, Durand JP, Boudou-Rouquette P, Michels J, Ropert S, Vidal M, Pol S, Chaussade S, Goldwasser F (2012) Sarcopeniapredicts early dose-limiting toxicities and pharmacokinetics of sorafenib inpatients with hepatocellular carcinoma. PLoS One 7 (5) : e37563.
15. Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R (1998) Cadaver validation of skeletal muscle measurement bymagnetic resonance imaging and computerized tomography. J ApplPhysiol 85 (1) : 115-122.
16. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, OudardS, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, SosmanJA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, FiglinRA (2009) Overall survival and updated results for sunitinib comparedwith interferon alfa in patients with metastatic renal cell carcinoma. J ClinOncol 27 (22) : 3584-3590.
17. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cellcarcinoma. N Engl J Med 356 (2) : 115-124.
18. Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE (2008) A practical and precise approach to quantification of bodycomposition in cancer patients using computed tomography imagesacquired during routine care. Appl Physiol Nutr Metab 33 (5) :997-1006.
19. Prado CM, Baracos VE, McCargar LJ, Mourtzakis M, Mulder KE, Reiman T, Butts CA, Scarfe AG, Sawyer MB (2007) Body composition as anindependent determinant of 5-fluorouracil-based chemotherapy toxicity.Clin Cancer Res 13 (11) : 3264-3268.
20. Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, Mackey JR, Koski S, Pituskin E, Sawyer MB (2009) Sarcopenia as adeterminant of chemotherapy toxicity and time to tumor progression inmetastatic breast cancer patients receiving capecitabine treatment. ClinCancer Res 15 (8) : 2920-2926.
21. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, BaracosVE (2008) Prevalence and clinical implications of sarcopenic obesity inpatients with solid tumours of the respiratory and gastrointestinal tracts: apopulation-based study. Lancet Oncol 9 (7) : 629-635.
22. Prado CM, Lima IS, Baracos VE, Bies RR, McCargar LJ, Reiman T, Mackey JR, Kuzma M, Damaraju VL, Sawyer MB (2011) An exploratory study of bodycomposition as a determinant of epirubicin pharmacokinetics and toxicity.Cancer Chemother Pharmacol 67 (1) : 93-101.
23. Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, Heymsfield SB, Heshka S (2004) Total body skeletal muscle and adiposetissue volumes: estimation from a single abdominal cross-sectional image.J Appl Physiol 97 (6) : 2333-2338.
24. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer JClin 62 (1) : 10-29.
25. Telli ML, Witteles RM, Fisher GA, Srinivas S (2008) Cardiotoxicity associated withthe cancer therapeutic agent sunitinib malate. Ann Oncol 19 (9) : 1613-1618.
26. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, GwytherSG (2000) New guidelines to evaluate the response to treatment in solidtumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Instituteof Canada. J Natl Cancer Inst 92 (3) : 205-216.
27. van der Veldt AA, Boven E, Helgason HH, van Wouwe M, Berkhof J, de GastG, Mallo H, Tillier CN, van den Eertwegh AJ, Haanen JB (2008) Predictivefactors for severe toxicity of sunitinib in unselected patients with advancedrenal cell cancer. Br J Cancer 99 (2) : 259-265.
28. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S (2006) Discovery and development of sorafenib:a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 5 (10) :835-844.